The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations

Oncogene

Volumn 27, Issue 22, 2008, Pages 3102-3110

  Odgerel, T ^a   Kikuchi, J ^a   Wada, T ^a   Shimizu, R ^a   Futaki, K ^a   Kano, Y ^b   Furukawa, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

Author keywords

Bad; CDC2; CDC25; Cell cycle; FLT3 inhibitor; Leukemia

Indexed keywords

CD135 ANTIGEN; CDC25C PHOSPHATASE; CYCLIN DEPENDENT KINASE 1; MIDOSTAURIN; PROTEIN; PROTEIN BAD; PROTEIN MYT 1; PROTEIN TYROSINE PHOSPHATASE; SERINE;

ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL STRAIN U937; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LEUKEMIA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PHOSPHORYLATION; SERINE; SIGNAL TRANSDUCTION; STAUROSPORINE; U937 CELLS;

EID: 43749094570     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210980     Document Type: Article

References (29)

1. Begemann M, Kashimawo SA, Heitjan DF, Schiff PB, Bruce JN, Weinstein IB. (1998). Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anticancer Res 18: 2275-2282.
2. Donovan N, Becker EB, Konishi Y, Bonni A. (2002). JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 277: 40944-40949.
3. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S et al. (2007). Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus negative leukemia cell lines. Leukemia 21: 1005-1014.
4. Galaktionov K, Jessus C, Beach D. (1995). Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev 9: 1046-1058.
5. Galonek HL, Hardwick JM. (2006). Upgrading the bcl-2 network. Nat Cell Biol 12: 1317-1319.
6. Gilliland DG, Griffin JD. (2002). The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532-1542.
7. Green DR. (2006). At the gates of death. Cancer Cell 9: 328-330.
8. Griffin JD. (2004). FLT3 tyrosine kinase as a target in acute leukemias. Hematol J 5: 188-190.
9. Ikegami Y, Yano S, Nakao K. (1996). Effects of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneimittelforschung 46: 201-204.
10. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. (2002). FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99: 310-318.
11. Kim KT, Levis M, Small D. (2006). Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol 134: 500-509.
12. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K et al. (1997). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 11: 1447-1452.
13. Konishi Y, Lehtinen M, Donovan N, Bonni A. (2002). Cdc2 phosphorylation of BAD Links the cell cycle to the cell death machinery. Mol Cell 9: 1005-1016.
14. Levis M, Pham R, Smith BD, Small D. (2004). In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 104: 1145-1150.
15. Levis M, Small D. (2005). FLT3 tyrosine kinase inhibitors. Int J Hematol 82: 100-107.
16. Lopez-Girona A, Furnari B, Mondesert O, Russell P. (1999). Nuclear localization of Cdc25 is regulated by DNA damage and a14-3-3 protein. Nature 397: 172-175.
17. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B et al. (1993). Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75: 1157-1167.
18. Neben K, Schnittger S, Bross B, Tews B, Kokocinski F, Haferlach T et al. (2005). Distinct gene expressions patterns associated with FLT3- and NRAS- activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 24: 1580-1588.
19. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP et al. (2001). Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19: 1485-1492.
20. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. (2003). FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17: 120-124.
21. Schmitt E, Beauchemin M, Bertrand R. (2007). Nuclear colocalization and interaction between bcl-xL and cdk1 (cdc2) during G2/M cell-cycle checkpoint. Oncogene 26: 5851-5865.
22. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91: 459-463.
23. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. (2005). Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54-60.
24. Watanabe N, Broome M, Hunter T. (1995). Regulation of the human Wee1 CDK tyrosine 15 kinase during cell cycle. EMBO J 14: 1878-1891.
25. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T et al. (2002). Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1: 433-443.
26. Yang X, Lui L, Sternberg D, Tang L, Galinsky I, DeAngelo D et al. (2005). The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin 3-deprived BaF3 cells due to protein kinase A and ribosomal S6 Kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res 65: 7338-7347.
27. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. (2003). FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 9: 4483-4493.
28. Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T et al. (2004). Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104: 4202-4209.
29. Zha J, Harada H, Yang F, Jockel J, Korsmeyer SJ. (1996). Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 87: 619-628.